(Q42637668)

English

An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis

scientific article published on October 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis (English)

1 reference

Europe PubMed Central

4 November 2017

multiple sclerosis

0 references

author name string

T L Vollmer

1

1 reference

Europe PubMed Central

4 November 2017

J T Phillips

2

1 reference

Europe PubMed Central

4 November 2017

A D Goodman

3

1 reference

Europe PubMed Central

4 November 2017

M A Agius

4

1 reference

Europe PubMed Central

4 November 2017

M A Libonati

5

1 reference

Europe PubMed Central

4 November 2017

J L Giacchino

6

1 reference

Europe PubMed Central

4 November 2017

J S Grundy

7

1 reference

Europe PubMed Central

4 November 2017

publication date

1 October 2004

1 reference

Europe PubMed Central

4 November 2017

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

4 November 2017

10

1 reference

Europe PubMed Central

4 November 2017

5

1 reference

Europe PubMed Central

4 November 2017

511-520

1 reference

Europe PubMed Central

4 November 2017

Key issues in the diagnosis and treatment of multiple sclerosis. An overview

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Circulating adhesion molecules and inflammatory mediators in demyelination: a review

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

The role of integrins in immune-mediated diseases of the nervous system

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Adhesion Molecules in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Endothelial cell integrin laminin receptor expression in multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Role of the major histocompatibility complex class I antigens in tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Natalizumab for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1084OA

21 January 2018

Identifiers

10.1191/1352458504MS1084OA

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42637668&oldid=1963924935"